Review

Urinary titin N-fragment as a biomarker of muscle atrophy, intensive care unit-acquired weakness, and possible application for post-intensive care syndrome.

Nobuto Nakanishi 1,*, Rie Tsutsumi 2, Kanako Hara 2, Masafumi Matsuo 3, Hiroshi Sakaue 2, Jun Oto 1

1 Emergency and Critical Care Medicine, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima 770-8503, Japan; nobuto_nakanishi@yahoo.co.jp (N.N.); joto@tokushima-u.ac.jp (J.O.)
2 Department of Nutrition and Metabolism, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan; rtsutsumi@tokushima-u.ac.jp (R.T.); c201931015@tokushima-u.ac.jp (K.H.); hsakaue@tokushima-u.ac.jp (H.S)
3 Research Center for Locomotion Biology, Kobe Gakuin University, 518 Arise, Ikawadani, Nishi, Kobe 651-2180, Japan; matsuo@kobe-u.ac.jp (M.M.)
* Correspondence: nobuto_nakanishi@yahoo.co.jp; Tel. +81-88-631-7151

Abstract: Titin is a giant protein that functions as a molecular spring in sarcomeres. Titin interplays the contraction of actin-containing thin filaments and myosin-containing thick filaments. The breakdown product of titin has been measurable in urine as urinary titin N-fragments. Urinary titin N-fragment was originally reported to be a useful biomarker in the diagnosis of muscle dystrophy. Recently, the urinary titin N-fragment has been increasingly gaining attention as a novel biomarker of muscle atrophy and intensive care unit-acquired weakness in critically ill patients, in whom titin loss is a possible pathophysiology. Furthermore, several studies reported that the urinary titin N-fragment also reflected muscle atrophy and weakness in patients with chronic illnesses. It may be used to predict the risk of post-intensive care syndrome or to monitor patients’ condition after hospital discharge for better nutritional and rehabilitation management. We provide several tips on the use of this promising biomarker in post-intensive care syndrome.

Keywords: titin; muscle; diaphragm; atrophy; physical dysfunction, biomarker; urine; post-intensive care syndrome; nutrition; rehabilitation

1. Introduction

Titin, also called Connectin, is a giant sarcomere protein, which functions as a spring for muscle extension and elasticity [1]. Titin interplays the contraction of actin-containing thin filaments and myosin-containing thick filaments. Recently, the N-terminal fragment of titin, which is the breakdown product of titin, has become measurable using an enzyme-linked immunosorbent assay kit (27900 titin N-fragment Assay Kit; Immuno-Biological Laboratories, Fujioka, Japan) [2]. This kit has been used to evaluate muscle breakdown in muscle dystrophy, in which urinary titin N-fragment was increased 700-times above the normal level [3].

Muscle atrophy and weakness are common in critically ill patients [4]. Particularly, muscle weakness has been widely recognized as an intensive care unit-acquired (ICU)-acquired weakness (ICU-AW) [5]. Although the pathophysiology of ICU-AW is still unknown, Swist et al. found titin loss in the muscle biopsies of critically ill patients, and suggested that the titin loss was a cause of ICU-AW [6]. Two study groups have recently reported the utility of urinary titin N-fragment in ICU-AW. Nakanishi et al. found that the urinary titin N-fragment reflected muscle atrophy and ICU-AW in critically ill patients [7]. Moreover, the accumulated urinary titin was associated with mortality in...
these patients. On the other hand, another study group, by Nakano et al., reported that urinary titin can be a possible biomarker of muscle atrophy and ICU-AW [8, 9]. The urinary titin N-fragment may become an important test in the ICU.

The ICU-AW prolongs years after the ICU discharge, which is known as the post-intensive care syndrome (PICS) [10]. PICS is a state characterized by physical dysfunctions, psychological disorders, or cognitive impairments that persist beyond ICU discharge. The state prolongs even for five years after ICU discharge [11]. One of the important measures to reduce PICS is to follow-up high-risk patients after ICU discharge. The urinary titin N-fragment can be used as a biomarker to identify patients who exhibit increased catabolism and need intervention. We suggest several tips on how to properly use the urinary titin N-fragment in PICS. In this review, we summarized the recent literatures of titin and the possible applications of the urinary titin N-fragment to PICS.

2. Titin

Titin, initially known as Connectin, was discovered in 1976 by Maruyama et al. [12]. Then, being the largest protein in the human body, it was named titin after the giant god of Titan in Greek mythology. Titin is the largest protein in humans, which has 3.0 to 3.7 MDa. This protein is located in the muscle sarcomere, and interplays the contraction of actin-containing thin filaments and myosin-containing thick filaments. Passive tension and elasticity during muscle contraction develops as a result of the titin protein by Ca\(^{2+}\)-dependent stiffening (Figure 1) [1, 13].

![Figure 1. This is the schematic illustration of titin in the muscle. Muscle comprises of muscle fibers, myofibrils, and the smallest units known as sarcomeres. In the sarcomere, titin connects actin-containing thin filaments and myosin-containing thick filaments.](image)

During muscle degradation, titin is broken into small fragments, and several different fragments are measurable. In serum, the metalloproteinase (MMP) 2-cleaved titin fragment and MMP 12-cleaved titin fragment are measurable. MMP 2-cleaved titin reflected muscle atrophy in a human bed rest study [14]. On the other hand, MMP 12-cleaved titin fragment can be used to assess cardiac infarction because the fragment increased after an acute myocardial infarction [15].

Recently, the N-terminal fragment of titin, known as the urinary titin N-fragment, has become measurable in urine, which has 25 kDa. Unlike serum, this urinary biomarker is noninvasive, but requires correction by urinary creatinine to adjust for the kidney function. The standard value of urinary titin N-fragment was 2.1 (1.2–2.6) pmol/mg Cr in healthy adult volunteers [2].
3. Muscle atrophy

3.1. Limb and trunk muscle atrophy

Muscle atrophy is a serious problem in critically ill patients [4]. After one week of ICU admission, critically ill patients exhibit muscle atrophy of 13.2–16.9% and 18.8–20.7% in the upper and lower limbs, respectively [16]. These muscle atrophies are associated with impaired physical function and mortality [17, 18]. Muscle atrophy is caused by numerous factors, but occurs mainly due to inflammation and immobilization. Various inflammatory cytokines are associated with muscle atrophy [19]. On the other hand, immobilization causes muscle loss by 0.33% per day even in healthy volunteers [20]. In critically ill patients, immobilization often become the cause of muscle atrophy because it is frequently observed in the ICU [21].

Muscle mass can be assessed by computed tomography, bioelectrical impedance analysis, and ultrasound [22]. Computed tomography is accurate, but exposes patients to radiation, while the bioelectrical impedance analysis is influenced by fluid changes in critically ill patients [23]. Ultrasound can be used for the bedside monitoring of muscle atrophy, but it requires a skilled and experienced operator [24, 25]. Thus, a biomarker to assess muscle atrophy is urgently needed. In a rat study, Udaka et al. found that six weeks of immobilization caused titin loss in the soleus muscle, which was associated with muscle dysfunction [26]. Thus, it is theoretically reasonable that urinary titin is expected to be elevated in the urine of patients who are ongoing muscle atrophy.

In muscular dystrophy, the urinary titin N-fragment reflected the disease severity. Duchenne muscular dystrophy had a higher concentration of the urinary titin N-fragment than Becker muscular dystrophy (965.8 vs 171.2 pmol/mg Cr, p < 0.01) [27]. This result possibly reflects the amount of muscle breakdown in these conditions. Recently, two studies have reported the usefulness of the urinary titin N-fragment in the evaluation of muscle atrophy in critically ill patients. Nakano et al. also reported that urinary titin could be used to evaluate muscle atrophy in critically ill patients [9]. In their study investigating four critically ill patients, there was a negative correlation between mean urinary titin level during the first seven days of ICU admission and femoral muscle volume measured by computed tomography (r = -0.729). On the other hand, Nakanishi et al. reported that in 56 non-surgical critically ill patients, the cumulative urinary titin concentration on days 3, 5, and 7 was significantly higher in the prominent muscle atrophy group (p ≤ 0.03), suggesting that urinary titin reflects muscle atrophy in non-surgical critically ill patients [7]. However, in their study, the correlation between muscle atrophy and urinary titin was limited to r = 0.29–0.54 (p ≤ 0.03), suggesting that urinary titin is affected by various physiologic conditions. Since inflammation is an important cause of muscle atrophy, the peak urinary titin N-fragment level was higher in patients with sepsis (93.0 vs 57.9 pmol/mg Cr, p = 0.02). Moreover, the higher urinary titin N-fragment was associated with increased mortality. Although further studies are required, some relationship exists between muscle atrophy and urinary titin N-fragment.

3.2. Diaphragm muscle atrophy

Diaphragm atrophy is a serious problem in mechanically ventilated critically ill patients, in whom 60% of patients exhibits diaphragm atrophy [28]. The atrophy is associated with prolonged mechanical ventilation and prolonged ICU stay [29]. Diaphragm atrophy is the cause of diaphragm dysfunction, which has been recognized as a Ventilator Induced Diaphragm Dysfunction (VIDD) [30].

Titin plays an important role in the diaphragm contractile force [31], and titin loss was associated with diaphragm dysfunction in rats [32, 33]. Generally, diaphragm atrophy is caused by controlled mechanical ventilation or excessive ventilatory support [34]. Hussain et al. found in the diaphragm biopsy of human subjects that prolonged controlled mechanical ventilation decreased titin, and impaired the diaphragm myofibrillar force [35]. On the other hand, Lindqvist et al. suggested that
the positive-end expiratory pressure (PEEP) during ventilation led to the breakdown of the diaphragm titin because the PEEP stretched out the sarcomere of the diaphragm muscle fibers [36].

Although titin is associated with diaphragm atrophy and dysfunction, our previous study reported that urinary titin N-fragment was not higher in the diaphragm atrophy group compared to the unchanged group (147.9 vs. 192.4 pmol/mg in the unchanged vs. atrophy group, p = 0.33) [7]. The urinary titin N-fragment can measure the titin breakdown product in all muscles, and is not specific to the diaphragm. To quantify the diaphragm atrophy, a diaphragm-specific titin kit is necessary. It may be theoretically possible because a cardiac-specific titin kit was developed in another study [37].

Interestingly, several studies reported that increased diaphragm thickness has worse clinical outcomes as well as diaphragm atrophy [28, 29]. Insufficient ventilatory support leads to excessive respiratory effort in mechanically ventilated patients. This condition increases the diaphragm thickness. Since the increased muscle thickness has worse outcomes, the hypertrophied diaphragm may not have functional titin to properly work. In a previous study about urinary titin N-fragment, there was no significant difference in the cumulative urinary titin N-fragment between the unchanged diaphragm thickness and increased diaphragm thickness groups (147.9 [79.0–257.8] vs. 426.1 [140.8–578.2] pmol/mg Cr in unchanged vs. increased, p = 0.45) [7]. The combination of increased diaphragm thickness and atrophy also did not have a significant difference in terms of the cumulative urinary titin N-fragment (147.9 [79.0–257.8] vs. 206.5 [99.3–440.8] pmol/mg Cr in unchanged vs. combination, p = 0.31). The mechanism of increased diaphragm thickness remains to be elucidated.

Diaphragm dysfunction is preventable and reversible. It is therefore important to maintain spontaneous breathing and avoid excessive ventilatory support during mechanical ventilation, which is called diaphragm protective ventilation [29]. Diaphragm protective ventilation can prevent diaphragm atrophy, compared with lung protective ventilation [38]. On the other hand, O’Rourke et al. reported that percutaneous electrical phrenic nerve stimulation increased diaphragm thickness by 15.1% within 48 hours [39]. Extracorporeal support is also considered to prevent diaphragm injury [40], and in a case report, the early initiation of extracorporeal support prevented diaphragm atrophy, with a relatively suppressed urinary titin N-fragment of 24.1–38.4 pmol/mg Cr [41].

3.3. Other respiratory muscle atrophy

In addition to the diaphragm muscle, intercostal muscle atrophy is also observed in mechanically ventilated patients [42], and is associated with prolonged mechanical ventilation and prolonged ICU stay [28]. Moreover, muscle atrophy occurs in other expiratory muscles including the obliquus interna, obliquus externa, transversus abdominis, and rectus abdominis muscles [43]. In a case report of a mechanically ventilated patient, intercostal muscle biopsy showed the loss of myosin-containing thick filaments with the possible detachment of titin [44]. Titin loss may be an important cause of other respiratory muscle dysfunctions as well as that of the diaphragm. Jonkman et al. reported that breath-synchronized electrical stimulation increased the thickness of abdominal expiratory muscles (1.76 mm vs. −0.50 mm in intervention vs. control, p = 0.02) [45]. Thus, titin loss may be reversible by active rehabilitation.

4. ICU-acquired weakness

In the ICU, newly acquired muscle weakness is called ICU-acquired weakness (ICU-AW), which is found in 40–50% of all critically ill patients [4]. In a previous study, ICU-AW was independently associated with physical dysfunction at six months after ICU discharge [46]. The diagnosis of ICU-AW requires muscle strength assessment, basically by using a medical research council score < 48 [47], and the low medical research council score was associated with impaired physical functions including handgrip strength, 6-minute walking distance, and physical functioning of SF-36 even five years after ICU discharge [48]. Also, because the diagnosis of ICU-AW requires active cooperation of patients, the assessment is not feasible in about half of critically ill patients [4]. Thus, the development
of a biomarker is important to diagnose ICU-AW. However, there has been no established available biomarker to diagnose ICU-AW [49].

ICU-AW is classified into critical illness myopathy or neuropathy [5]. Although the mechanism is still unknown, the damage to myosin-containing thick filaments has been proposed to be a contributing factor of the critical illness myopathy [50, 51]. Recently, Swist et al. collected biopsies of the tibialis anterior muscles in nine mechanically ventilated ICU patients diagnosed with critical illness myopathy, and found that not only myosin-containing thick filaments, but also titin was lost in the muscle, whereas actin-containing thin filaments were unchanged [6]. In their other study, a titin-inactivated mouse had sarcomere disintegration, myocyte de-stiffening, and force impairment, which were consistent with the muscle damage of critical illness myopathy. Thus, they suggested that titin loss is a contributing factor of critical illness myopathy. On the other hand, Chen et al. investigated the role of titin in neuropathy [52]. They denervated the tibialis anterior muscles of rats, and measured the amount of titin in the muscle. In the denervated muscle, titin loss was observed, and the loss was dependent on the denervation time. They found that titin was translocated possibly cleaved from the sarcomere, and concluded that titin was sensitive to degradation after denervation.

Urinary titin N-fragment is useful to assess functional impairments. Ishihara et al. reported that urinary titin N-fragment correlated with functional impairments in patients after stroke [53]. In the study, peak urinary titin N-terminal fragment during the seven days of admission was correlated with the modified Rankin Scale score \( (r = 0.55, p < 0.01) \), National Institutes of Health Stroke Scale score \( (r = 0.72, p < 0.01) \), and Barthel index \( (r = -0.59, p < 0.01) \) at the time of hospital discharge. In the multivariate analysis adjusted for the disease severity, the urinary N-terminal fragment on day 2 predicted the functional outcome at hospital discharge (odds ratio, 1.11; 95% CI, 1.01–1.28). This study excluded patients with in-hospital onset, not having independent activities of daily living, dialysis, surgery, and seizure. Thus, it is reasonable to think that the urinary titin N-fragment reflected muscle breakdown and subsequent functional impairments.

Two studies groups have recently reported the usefulness of urinary titin N-fragment in ICU-AW. Nakanishi et al. investigated the urinary titin N-fragment in 56 non-surgical critically ill patients, and found that the cumulative urinary titin N-fragment till discharge or day 7 was higher in ICU-AW than non-ICU-AW patients \( (314.1 [181.5–464.7] \text{ vs } 86.6 [66.3–171.1], p = 0.01) \) [7]. In the study, urinary titin level on day 2 predicted ICU-AW with sensitivity of 78% and specificity of 81% at the cut-off value of 64.8 pmol/mg Cr. On the other hand, Nakano et al. investigated 50 consecutive critically ill patients, and found that the medical research council score was lower in the high urinary titin N-fragment group \( (37.0 [24.0–56.0] \text{ vs. } 56.0 [51.0–60.0], p = 0.023) \) [8]. In multivariate analysis, urinary titin N-fragment was independently associated with medical research council score < 48, almost equivalent with ICU-AW, after adjusting for age, sex, sequential organ failure assessment score, and steroid dose (adjusted odds ratio: 1.02 [95% CI: 1.00–1.03], p = 0.02). In their study, the mean urinary titin N-fragment level during the first 7 days of ICU admission predicted ICU-AW with a sensitivity of 61.9% and specificity of 89.7% at the cut-off value of 100 pmol/mg Cr. The area under the curve to predict medical research council score < 48 was 0.810 (95% CI: 0.688–0.931), whereas creatine kinase had an area under the curve of 0.654 (95% CI: 0.494–0.814). Since titin is a functional protein, it is theoretically understandable that urinary titin is a better biomarker of ICU-AW than creatine kinase, which is an enzyme found in various tissues [54]. Indeed, another study reported that creatinine kinase level did not differ in ICU-AW or non-ICU-AW patients (405 vs. 508 pmol/mg Cr, p = 0.10) [55].

It is beneficial if we predict ICU-AW using the urinary titin N-fragment because ICU-AW is a preventable condition. Nutritional support and rehabilitation can prevent ICU-AW [56]. In patients with risk of ICU-AW, we can provide intense nutrition and rehabilitation management. Moreover, we can avoid or at least reduce the risk medications including catecholamines, steroids, or neuromuscular blockers [51, 57, 58]. The measurement of urinary titin N-fragment may change our clinical practice regarding the management of critically ill patients.
5. PICS

PICS is a state characterized by physical, psychological, or cognitive impairments persisting beyond ICU discharge [10]. Acute respiratory distress syndrome survivors have prolonged muscle atrophy, impaired gait speed, and a deteriorated 6-minute walk distance at 6 to 12 months after ICU discharge [59]. These physical dysfunctions persist up to five years in some patients [11]. In a study, 46% of patients had persistent symptoms of ICU-AW from 5 to 10 years [60]. These prolonged physical dysfunctions hinder patients from returning to work [61].

These days, PICS has been gaining increased attention because of the aging society and the coronavirus disease 2019 (COVID-19) pandemic [62]. The elderly population is increasing worldwide, and this population has the high risk of PICS [10]. At 12 months after hospital discharge, the Barthel index was lower in patients above 75 years old than in 65 to 74 years old patients (p < 0.01) [63]. On the other hand, in COVID-19, muscle weakness lower than 48 was observed in 66% of patients [64], and ICU-AW was observed in 52% of patients at ICU discharge and 27% of patients at hospital discharge after the COVID-19 infection [65]. After the COVID-19 pandemic, the PICS pandemic is anticipated, requiring some preparation [66].

The loss of titin may be a cause of the prolonged physical dysfunction of PICS. We considered two hypotheses: 1) Prominent muscle breakdown in the ICU, 2) Prolonged muscle breakdown after hospital discharge (Figure 2).

![Figure 2](image-url). This is a conceptual image of urinary titin N-fragment and muscle weakness in PICS. In PICS, urinary titin N-fragment may be elevated due to the prominent muscle breakdown in the acute phase or prolonged muscle breakdown in the chronic phase, leading to the muscle weakness after hospital discharge. PICS: post-intensive care syndrome.

First, prominent muscle breakdown will lead to increased muscle atrophy and weakness. The change in the acute phase may prolong into the PICS. There are several strategies to prevent the prominent muscle breakdown in the acute phase. Rehabilitation has proven to be effective in preventing muscle atrophy and physical dysfunction [67, 68]. Nakanishi et al. reported that electrical muscle stimulation was effective in preventing muscle breakdown [69]. In the study, blood branched-chain amino acid, which is an important muscle component, was investigated, and the amino acid level was lower in the patients who received the electrical muscle stimulation intervention (40.5% [-7.4% to 75.3%] vs. 71.5% [38.8% to 116.9%]), suggesting a decrease in muscle breakdown. Another strategy is to ensure sufficient protein intake during the acute phase. Nakamura et al. reported that protein intake of 1.5 g/kg/day prevented muscle atrophy during the first 10 days of ICU admission,
compared with 0.8 g/kg/day (12.9% ± 8.5% vs. 16.9% ± 7.0% in 1.5 vs. 0.8 g/kg/day, p < 0.01) [70]. These strategies in the acute phase will possibly prevent PICS.

Second, patients with PICS may have prolonged muscle breakdown due to the chronic inflammation or decreased mobility. Some patients experience chronic inflammation, which is called the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome [71]. This condition may be caused by various conditions including disseminated intravascular coagulopathy [72] and electrolyte imbalance [73]. Chronic inflammation is known to cause muscle atrophy [74]. On the other hand, decreased mobility is also a cause of prolonged muscle breakdown. After hospital discharge, impaired physical function or endurable pain will lead to decreased mobility [75]. Although early mobilization is important to prevent physical dysfunction, Fuke et al. reported that early mobilization is not sufficient to prevent PICS [76]. One of the strategies to prevent PICS is following-up the patient after the hospital discharge. Although PICS follow-up has been shown to decrease mortality and medical cost [77], few facilities conduct PICS follow-up. In most facilities, human resources and financial support are not sufficient to conduct the PICS follow-up [78]. Thus, the international consensus conference of critical care medicine recommended to select the patients to follow-up, and the selection should be conducted within 2–4 weeks after hospital discharge [79].

We consider that the urinary titin N-fragment may be an important test for screening, follow-up, and management. Urinary titin N-fragment reflects ongoing muscle breakdown because the fragment can detect muscle breakdown at least within 2 hours of its onset [53]. The measurement of urinary titin N-fragment can identify patients at high risk of prolonged muscle breakdown. In a previous report, Oshida et al. investigated the level of urinary titin N-fragment in patients with non-alcoholic fatty liver disease [80]. They found that the urinary titin N-fragment was negatively correlated with skeletal muscle mass (r = -0.134, p < 0.05), grip strength (r = -0.203, p < 0.01), and knee extension muscle strength (r = -0.191, p < 0.05), and positively correlated with the echo intensity of the rectus femoris muscle (r = 0.361, p < 0.001), which indicates the fibrous changes of the muscle tissue [81]. Although the reported average of urinary titin N-fragment concentration is 2.1 (1.2–2.6) pmol/mg/Cr, the level was increased several times in some patients with and without non-alcoholic fatty liver disease. Another study by Miyoshi et al. investigated patients with gastrointestinal tract and hepatobiliary pancreatic malignancies, and found that the urinary titin N-fragment was significantly higher in sarcopenia (8.3 [1.9–20] vs. 4.9 [2.3–15] pmol/mg Cr, p = 0.04) [82]. In their study, urinary titin N-fragment showed statistically significant negative correlations with skeletal muscle volume index (r = -0.16, p = 0.04). These two studies suggest that the urinary titin N-fragment may be utilized to assess the muscle breakdown state in PICS.

Before we use the urinary titin N-fragment in clinical practice, we need to know several tips. First, spot urine test is available for the urinary titin N-fragment. Although the 24-hour urine sample looks reliable, it is not feasible during the follow-up. In urinary titin N-fragment, circadian variations are limited [83]. Second, surgical procedures may increase the urinary titin N-fragment. It is theoretically reasonable, and urinary titin N-fragment was indeed elevated shortly after a cardiac surgery [84]. Third, the standard level of the urinary titin N-fragment differs according to age. Age is associated with muscle atrophy due to the increased catabolism [85]. Indeed, in a previous study, the average urinary titin N-fragment was 2.3 ± 1.4 pmol/mg Cr in less than 30 years old, 4.3 ± 3.7 pmol/mg Cr in 31 to 60 years old, and 5.7 ± 4.0 pmol/mg Cr in more than 60 years old patients [80]. In another study, urinary titin N-fragment was correlated with age (r = 0.11, p = 0.04) [82]. Fourth, active exercise should be refrained before the measurement of urinary titin N-fragment because exercise increases the urinary titin N-fragment [86, 87]. Due to the elastic property of titin, eccentric exercises are more injurious to the titin of muscle than concentric exercise [88]. Another study investigated the change of urinary titin N-fragment in people playing soccer match, and they found that the urinary titin N-fragment was increased during the 24 hours of soccer match and returned to the baseline value at 48 hours after the match [89]. The increased urinary titin N-fragment generally remains for 2–3 days after the exercise [2]. Fifth, urinary titin N-fragment is also increased by cardiac damage because the urinary titin N-fragment reflects the breakdown products of titin, including the cardiac source. Titin
loss is a contributing factor of dilated cardiomyopathy [90]. In a previous study, increased urinary titin N-fragment predicted the mortality in patients with dilated cardiomyopathy (p < 0.05) [91]. We summarized several factors that lead to an increase in the urinary titin N-fragment supported by various studies (Table 1).

Table 1. Factors leading to an increase in the urinary titin N-fragment

<table>
<thead>
<tr>
<th>Factors</th>
<th>Level of urinary titin N-fragment</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>2.3, 4.3, 5.7 pmol/mg/Cr in ≤ 30, 31–60, ≥ 61 years old</td>
<td>(80)</td>
</tr>
<tr>
<td>Exercise</td>
<td>40–100 pmol/mg/Cr in exercise-induced muscle damage</td>
<td>(87, 88)</td>
</tr>
<tr>
<td>Surgery</td>
<td>30–50 pmol/mg/Cr after cardiac surgery</td>
<td>(84)</td>
</tr>
<tr>
<td>Cardiac damage</td>
<td>≥ 7.26 pmol/mg/Cr in a third of dilated cardiomyopathy</td>
<td>(91)</td>
</tr>
</tbody>
</table>

We can intervene if patients have increased urinary titin N-fragment after hospital discharge. Nutrition and rehabilitation interventions are important in PICS [92]. After hospital discharge, continuous physical therapy is important in home or community-based settings [93]. In the exploratory analyses of a randomize controlled trial, continuous rehabilitation after hospital discharge led to the improvement of the 6-minutes walking distance at the 12 months follow-up [94]. Some patients may have persisting inflammation, but exercise has anti-inflammatory effects [95], and physical therapy is expected to reduce the inflammatory reaction [96]. Nutritional support prevents muscle breakdown in the chronic phase [97]. Regarding titin, Ulanova et al. reported that L-arginine administration decreased the loss of titin in the rat soleus muscle [98]. Since the nutritional support team involvement can improve calories and protein delivery [99, 100], a multidisciplinary team intervention is expected to be important in PICS if the urinary titin is elevated in the patients.

6. Conclusions

Titin plays an important role in the muscle, and urinary titin N-fragment can measure muscle breakdown in critically ill patients and possibly in PICS. As reported in muscle dystrophy, urinary titin N-fragment reflected the extent of muscle atrophy in critically ill patients. Furthermore, urinary titin N-fragment reflected the muscle weakness, consistent with the functional role of the urinary titin N-fragment. It is important to note that the urinary titin N-fragment increases with age, exercise, surgery, and cardiac damage, in addition to muscle atrophy and weakness. Our results indicate that urinary titin N-fragment may be a marker in PICS to identify patients with increased catabolism, requiring interventional support.

Author Contributions: NN, RT, and KH were involved in the drafting of the manuscript. MM, HS, and JO supervised and took part in the revision of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a crowdfunding project entitled the Muscle Atrophy Zero Project, using the platform “Otsucle” <https://otsucle.jp/cf/project/2553.html>. This work was partially supported by JSPS KAKENHI Grant Number JP20K17899.

Acknowledgments: The authors thank people who supported the Muscle Atrophy Zero Project, which aims to prevent muscle atrophy in critically ill patients. This work was partially supported by JSPS KAKENHI Grant Number JP20K17899.

Conflicts of Interest: The authors declare no conflict of interest.
References


of Duchenne muscular dystrophy. *Neuromuscul Disord* 2014, 24, 563-573, doi:10.1016/j.nmd.2014.03.012


